Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04614740
Other study ID # VC004-101
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date November 20, 2020
Est. completion date June 30, 2024

Study information

Verified date October 2022
Source Jiangsu vcare pharmaceutical technology co., LTD
Contact xiaojuan lai
Phone 15358160458
Email lai_xiaojuan@vcarepharmatech.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Dose-escalation study will be conducted in patients with locally advanced/metastatic solid tumors who have failed standard treatment, or cannot tolerate standard treatment, or have no recommended standard treatment, or do not apply standard treatment, to evaluate the safety, PK, tolerability and effectiveness of VC004. According to the efficacy, safety and PK of dose-escalation study , the investigator and the sponsor jointly determine the dose for dose extension, and evaluate the anti-tumor effect of VC004 on NTRK fusion-positive subjects, and provide more information for RP2D. According to the tolerability and pharmacokinetic results of dose-escalation study , an appropriate dose or MTD will be selected, namely RP2D, to further assess anti-tumor efficacy and safety in patients with NTRK fusion-positive locally advanced/metastatic solid tumors . ORR will be chosen as the main efficacy indicator to evaluate the anti-tumor efficacy and safety of VC004 .


Recruitment information / eligibility

Status Recruiting
Enrollment 115
Est. completion date June 30, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All subjects or legal representatives are willing and able to sign ICF approved by the ethics committee before starting any screening procedures; - Male or female, age =18 years old - Patients with locally advanced or metastatic solid tumors diagnosed by histology or cytology, or currently have no standard treatment, have failed the standard treatment, or are intolerant to the standard treatment or are not suitable for the standard treatment at this stage? The first part of the dose escalation stage: locally advanced or metastatic solid tumors, including but not limited to salivary gland cancer, thyroid cancer, soft tissue sarcoma, liposarcoma, etc. - Subject's baseline lesion requirements: According to the definition of RECIST v1.1 or RANO, the subject must have at least one measurable lesion (applicable to NTRK fusion-positive locally advanced or metastatic solid tumors)? - Subjects with primary central nervous system (CNS) tumors must meet the following criteria (only the first part of the dose expansion phase and the second part are applicable) - According to the guidelines or CNS tumor type, have received treatment including radiotherapy and/or chemotherapy, and the interval between radiotherapy and the first treatment with study drug is at least 12 weeks. - According to the definition of RANO, there is at least one measurable lesion in magnetic resonance imaging (MRI), which can be visualized on =2 axial films with a thickness of 5 mm, and the longitudinal diameters perpendicular to each other are> 10 mm. - The imaging examination was performed within 28 days before enrollment. If you receive glucocorticoid treatment, a stable dose of glucocorticoid is required at least 5 days before imaging evaluation. - The Eastern Cooperative Oncology Group (ECOG) score is =2 points (0-1 points are required for the dose-escalation stage) - The estimated survival time is =12 weeks. - The subject must have appropriate organ and hematological functions (have not received blood transfusion, EPO, G-CSF or other medical supportive treatment within 14 days before the administration of the study drug)? - Premenopausal women who are likely to have children must have a pregnancy test within 7 days before starting treatment. The pregnancy test must be negative and must be non-lactating; Infertile women may not undergo pregnancy tests and contraception, but they must meet the following requirements: age 50 years or older, not using hormone therapy and menopause for at least 12 months, or have undergone sterilization. All enrolled patients (whether male or female) should take adequate contraceptive measures throughout the treatment period and 180 days after the end of treatment. Exclusion Criteria: - Patients have previously received any of the following treatments: - Patients have used any cytotoxic chemotherapeutic agents, targeted therapies, immunotherapies, or other anti-cancer drugs in the previous regimen within 4 weeks before the first administration ( e.g.Nitrosourea or mitomycin C for 6 weeks prior to first use of study drug, Oral fluorouracil and small-molecule targeted drugs are administered 2 weeks prior to the first use of the study drug or within 5 half-lives of the drug, whichever is longer.). - The time from receiving other experimental drugs or analogues to the first dose does not exceed the drug's 5 half-life or 14 days (whichever is longer). - Patients have used chinese herbal medicines and chinese herbal preparations with antitumor as an indication, chinese herbal medicines and chinese herbal preparations with tumor adjuvant therapeutic effect within 14 days before the first administration. - Patients have undergone major surgery within 4 weeks prior to the first dose or are expected to undergo major surgery during the trial (excluding vascular access establishment procedures, biopsy procedures) - Adverse reactions caused by previous treatment have not recovered to =1 grade (the dose-escalation stage does not include =2 grade hair loss, and the dose expansion stage and phase II clinical trials are comprehensively evaluated by the investigator). - Primary central nervous system malignancy (only the first part of the dose escalation phase). - Patients are known to have symptomatic or untreated brain metastases or other central nervous system metastases.CNS lesions that remain stable or show improvement after treatment with complete resection and/or radiation therapy are excluded, but require no glucocorticoids to control neurological symptoms within 14 days prior to entry into this study. - There is any clinical basis suggesting a severe or uncontrolled systemic disease for which the investigator believes the patient is unsuitable for trial participation or which would affect the patient's compliance with the study protocol, such as stable or decompensated respiratory disease, cerebrovascular disease, liver disease, renal disease, uncontrolled diabetes, aortic dissection, aortic aneurysm, active bleeding-prone body, or those requiring systemic anti-infective therapy. - Any clinically serious gastrointestinal abnormality that may affect the ingestion, transit, or absorption of study drugs. - Patients have clinically significant cardiovascular diseases, including: - Left ventricular ejection fraction (LVEF) = 50% by echocardiography during the screening period - Heart Failure, New York Heart Association (NYHA) grade III and above - Poorly controlled hypertension (BP = 150/100 mmHg despite use of optimal therapy) - Past or current cardiomyopathy - Patients with atrial fibrillation and severe arrhythmia with ventricular rate> 100 bpm - Unstable ischemic heart disease (myocardial infarction (MI) within 6 months prior to starting study treatment, or angina that requires >1 nitrate per week to control symptoms) - QTcF interval =450ms for males and =470ms for females (Fredericka formula: QTcF = QT/RR0.33) - Patients had been treated with a strong CYP3A inhibitor or inducer within 7 days prior to the first administration of the study drug. - Currently existing hepatitis B (hepatitis B surface antigen [HbsAg] positive or core antibody [HbcAb] positive and HBV DNA positive), hepatitis C (HCV anti-positive and HCV RNA positive), human immunodeficiency virus (HIV) infection and syphilis infection. - Patients whom the investigators determine are not suitable for participation in the study for other reasons. - Subjects are unwilling or unable to follow the protocol process.

Study Design


Intervention

Drug:
VC004
25 mg capsules,50 mg capsules,100 mg capsules.

Locations

Country Name City State
China Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College Beijing
China Hunan Cancer Hospital Changsha Hu Nan
China Chongqing University Cancer Hospital Chongqing Chongqing
China Fujian Cancer Hospital Fuzhou Fujian
China Zhujiang Hospital of Southern Medical University Guangzhou
China Hainan Cancer Hospital Haikou Hainan
China Zhejiang Cancer Hospital Hangzhou Zhejiang
China Harbin Medical Univercity Cancer Hospital Harbin Heilongjiang
China Anhui Provincial Cancer Hospital Hefei Anhui
China Shandong Cancer Hospital Jinan Shandong
China Yunnan Cancer Hospital Kunming Yunnan
China Jiangsu Province Hospital of Chinese Medicine Nanjing Jiang Su
China Guangxi Medical University Affiliated Tumor Hospital Nanning Guangxi
China Shanghai Tenth People's Hospital Shanghai Shanghai
China Liaoning Cancer Hospital & Institute Shenyang
China The Fourth Hospital of Hebei Medical University Shijiazhuang Hebei
China Shanxi Provincial Cancer Hospital Taiyuan Shanxi
China Tianjin Cancer Hospital Tianjin
China The First Affiliated Hospital of Xinjiang Medical University Ürümqi
China Hubei Cancer Hospital Wuhan
China Henan Cancer Hospital Zhengzhou He Nan

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu vcare pharmaceutical technology co., LTD

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety&Tolerability Adverse events (CTCAE5.0)and/or laboratory testsand/or electrocardiogramand/or echocardiogramand/or vital signsand/or physical examination 4 years
Primary Phase II recommended dose(RP2D) According to the tolerability and pharmacokinetic results of different dose groups completed during the dose escalation phase, an appropriate dose or MTD is selected as RP2D 1.5 years
Primary Maximum tolerated dose(MTD)(If any) If =2 cases of DLT are observed at a certain dose (up to 6 subjects), the dose will be considered an intolerable dose, and the previous dose group will be regarded as MTD 1.5 years
Primary Objective response rate(ORR) The proportion of subjects whose best overall response is CR or PR in the study assessed by IRC/investigator according to RECIST v1.1 or RANO 4 years
Secondary Maximum Observed Plasma Concentration (Cmax) 0 min ,15 min,30 min,1 hour (h),2 h,3 h,4 h,6 h,8 h,12 h,24 h,48 h
Secondary Peak time(Tmax) 0 min ,15 min,30 min,1 hour (h),2 h,3 h,4 h,6 h,8 h,12 h,24 h,48 h
Secondary half-time(t1/2) 0 min ,15 min,30 min,1 hour (h),2 h,3 h,4 h,6 h,8 h,12 h,24 h,48 h
Secondary Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC) 0 min ,15 min,30 min,1 hour (h),2 h,3 h,4 h,6 h,8 h,12 h,24 h,48 h
Secondary Apparent volume of distribution(Vz/F) 0 min ,15 min,30 min,1 hour (h),2 h,3 h,4 h,6 h,8 h,12 h,24 h,48 h
Secondary Duration of Remission (DOR) Time from the first recording of remission (CR or PR) to the first recording of disease progression or death (whichever occurs first) 2.5 years
Secondary Progression-free survival (PFS) The time from the subject receiving the first study treatment to the appearance of disease progression or death from any cause (whichever occurs first) 2.5 years
Secondary Overall survival (OS) The time from the date of first medication to the date of death from any cause 2.5years
See also
  Status Clinical Trial Phase
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT05071183 - A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT05530200 - PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors. Phase 2
Active, not recruiting NCT04447651 - Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
Recruiting NCT04419532 - A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04137900 - Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies Phase 1
Recruiting NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Phase 1/Phase 2
Not yet recruiting NCT05028478 - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT05471271 - IL-2 PET Imaging in Advanced Solid Tumours N/A
Recruiting NCT05867121 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT03964727 - Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors Phase 2
Recruiting NCT06108050 - JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors Phase 1
Recruiting NCT05688280 - Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS Phase 1/Phase 2
Completed NCT04914117 - A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours Phase 1
Completed NCT00997529 - Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors N/A
Recruiting NCT06163391 - A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer Phase 1
Not yet recruiting NCT06415487 - ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) Phase 1
Recruiting NCT05824975 - A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors Phase 1/Phase 2